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Abstract Cardiovascular diseases are the leading cause
of mortality, morbidity, hospitalization and impaired
quality of life. In most, if not all, pathologic cardiac
ischemia ensues triggering a succession of events leading
to massive death of cardiomyocytes, ﬁbroblast and extra-
cellular matrix accumulation, cardiomyocyte hypertrophy
which culminates in heart failure and eventually death.
Though current pharmacological treatment is able to delay
the succession of events and as a consequence the devel-
opment of heart failure, the only currently available and
effective treatment of end-stage heart failure is heart
transplantation. However, donor heart availability and
immunorejection upon transplantation seriously limit the
applicability. Cardiac regeneration could provide a solu-
tion, making real a dream of both scientist and clinician in
the previous century and ending an ongoing challenge for
this century. In this review, we present a basic overview of
the various cell types that have been used in both the
clinical and research setting with respect to myocardial
differentiation.
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1 Myocardial regeneration
A little over a decade ago, it was generally accepted that
the human heart is a terminally differentiated organ lacking
any intrinsic regenerative capacity. After birth, the
cardiomyocytes undergo a ﬁnal round of cell division with
a portion of the cardiomyocytes becoming binuclear and/or
polypoid [14, 82, 83]. The observed post-natal growth is
attributed to mainly to hypertrophic growth of the resident
cardiomyocytes [76], with very no contribution of cell
division. In line with these ﬁndings it was observed that
amputation of the ventricular apex at 1 day after birth in
mice tolerates full regeneration of this region, whereas at
7 days post natal this capacity is completely lost [57].
The dogma that the adult heart is a post-mitotic organ,
was challenged for the ﬁrst time in 1998 by Kajstura et al.
[37], who showed that a small (0.001%) portion of
cardiomyocytes undergo mitosis in normal hearts. Though
numerous subsequent follow-up studies have reported
slightly differing numbers, the issue remained controver-
sial. Bergmann et al. [12], ﬁnally added real weight to the
idea that cardiomyocytes can and do undergo mitosis in
adult hearts, using C14 radiocarbon dating of human
genomic DNA. This experiment resembles that of a pulse-
chase experiment in which genomic DNA was labelled as a
result of trace amounts of radioactive nuclear fallout pro-
duced as a result of nuclear weapons testing during the cold
war. According to their study, at the age of 25 cardio-
myocytes have a mitotic turn-over of approximately 1%
per year. Although this value gradually decreases with age,
the numbers suggest that about 50% of resident cardio-
myocytes are renewed during life. These ﬁndings were also
found to be in line with mouse data [66]. However, the
initial challengers of the dogma, revisited and expanded
their initial study using state of the art tools [38] reporting a
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Interestingly, based on their methods and estimations the
cardiomyocytes of the heart would are renewed 10-times
during a normal life span.
Although this long lasting discussion has regained a
renewed interest, it is evident that the adult human heart has
a limited endogenous regenerative capacity. This capacity is
insufﬁcient (1) to maintain the number of cardiomyocytes
during aging and (2) to replace cardiomyocytes lost upon
injury and/or disease, leading to decreased heart function
and eventually heart failure. This contrasts sharply to the
high regenerative capacity found in teleosts and amphibians
[6]. A second question directly relating to this endogenous
regenerative capacity is the cellular origin of the newly
formed cardiomyocytes. The regenerated cardiomyocytes
are either derived from cells located within or outside the
heart. The quest for progenitors of cardiomyocytes within
the heart has led to the identiﬁcation of a multitude of car-
diac stem cells or progenitors, each with a different
molecular signature [41, 53]. cKit (CD117) and Flk-1 are
but two of the markers used to identify precursor cells
contributing to the cardiomyocyte, smooth muscle and
endocardial lineage. FACS sorting of the cKit-positive
population revealed that their contribution to the heart
gradually decreases with age, from 0.65%, of which 10% is
CD45-(hematopoietic)positive, in neonatal mouse heart to
0.5%, of which 15% is CD45-positive, in the adult heart
[88]. Such cells can also be isolated from the human heart as
well. Though absolute numbers are not known, they are
rare and their number also decreases with age [29, 30].
Co-culturing neonatal cKit-positive cells with foetal
cardiomyocytes results in robust differentiation into cardio-
myocytes, whereas adult cKit-positive cells appear to have
lostthiscapacity.Invivotestingusingmousemodelsrevealed
that injecting these cells into an infarct showed no signiﬁcant
differentiation into cardiomyocytes [10, 29, 30, 88].
Though it is currently accepted that cardiac stem cells or
progenitors exist, it is as yet not known what factors are
needed to expand this population and to induce their dif-
ferentiation into functional cardiomyocytes.
2 (Human) Embryonic stem cells derivation
and potential
With the derivation of the ﬁrst human embryonic stem cells
(hESC) by Thomson et al. [73], the ﬁeld of stem cell
research caught the scientiﬁc and public domain’s atten-
tion, bringing an understandable high level of hope for new
breakthroughs in regenerative medicine. Despite the
ensuing reactions regarding the ethical issues that surround
the isolation and use of cells that are of a human embryonic
origin, the prospect of being able to treat a multiplicity of
diseases, particularly the appeal of ﬁnally being able to
restore function of tissue lost during a myocardial infarct,
stem cell research took off at an incredible rate (Fig. 1).
However, apart from the ethical issues surrounding this
research, hESC, as we shall discuss, have thrown up
many obstacles on their route to the clinic resulting in a
re-evaluation of strategies being taken to implement their
use. Although other ‘stem cell’ sources have been applied
more readily in the clinical setting, hESCs have only just
received the ﬁrst green light for an FDA approved human
trial to investigate their applicability for the treatment of
complete thoracic spinal severance [2].
Embryonic stem cells are derived from the inner cell
mass of the blastocyst *5 days post fertilization. Given
the diverse and sometimes incorrect use of the word stem
cell, ESC were described using the physical characteristics
(i) derived from the pre-implanted embryo, (ii) prolonged,
undifferentiated proliferation and (iii) the potential to
develop and give rise to all three germinal layers (endo-
derm, mesoderm and ectoderm) [72]. The molecular deﬁ-
nition of hESC remains a challenge, due in part to the
heterogeneity that already exists even at the blastocyst
stage. This is perhaps not surprising since the inner cell
mass will rapidly give rise to the ordered three layered
germinal disc from which the embryo will develop. Cells
may therefore even at this stage differ from their neigh-
bouring cells and begin to display the molecular charac-
teristics of one of the germinal layers, which in turn could
be composed of cells that differ from each other. However,
markers, have been identiﬁed which serve as tools for
sorting and cellular selection.
The two glycosphingolipid surface antigen markers
SSEA-3 and SSEA-4 are, are identiﬁed on human embry-
onal carcinoma (EC) cell lines, on early cell-cleavage
mouse embryos [40] and later on cells of the inner cell
mass of human blastocysts [33]. In contrast to mice, which
have lost expression of these antigens by the blastocyst
stage, these markers along with two others also identiﬁed
previously in human EC cells (TRA-1-60 and TRA-1-81
[4]) appear to become down-regulated during differentia-
tion, a feature which is also observed in hESC cultures
exposed to retinoic acid [23, 33]. Although the exact
molecular deﬁnition of these surface markers remains to be
resolved, experiments suggest that they represent carbo-
hydrate modiﬁcations, possibly linked to the glycoprotein
podocalyxin [51, 64]. The expression of these markers on
hESC and their subsequent loss during differentiation
suggests a critical functional role in cell pluripotency.
Experiments involving the depletion of SSEA-3 and SSEA-
4 on hESCs using inhibitors of sphingolipid synthesis
appear to show that these markers do not play a critical role
in maintenance of the undifferentiated state [13]. Although
the function of most of the cell surface markers used for
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unique markers is obvious and remains an area of keen
research. For instance, a recent monoclonal antibody
screen by Choi et al. [19] has identiﬁed a novel surface
molecule, E1B-AP5 which co-localizes together with
SSEA-3, SSEA-4, TRA-1-60 and TRA-1-81 and becomes
down-regulated during differentiation. However, unlike
these markers, E1B-AP5’s molecular identity is better
deﬁned, representing an adenovirus nuclear RNA-binding
protein which appears to also be expressed at the plasma
membrane as well as in the nucleus of hESC cells.
A further, perhaps more comprehensive, approach to
characterizing undifferentiated hESCs has been brought
about by the introduction of high-throughput molecular
techniques such as microarrays, ChIP-seq and RNA-seq
(reviewed in [32]). This work has led to the identiﬁcation
of a core set of transcription factors consisting of OCT3/4
(also known as POU5F1), the sex determining region Y
protein SOX2, the homeobox protein NANOG and the
PR-domain containing zinc ﬁnger protein PRDM14 [18].
These factors are key in the process of pluripotency
maintenance, though their individual expression patterns
are not all restricted to this earliest phase of development,
many being required during later key differentiation and
cell lineage decisions. Not coincidently then, SOX2 and
OCT3/4 constitute 2 of the factors used in the initial studies
aimed at direct reprogramming of somatic cells to plurip-
otent stem-like cells (iPS) [67]. The issues and details
surrounding iPS cells will be discussed later. In line with
this, work from early 2000 demonstrated that a reduction of
Oct3/4 led to a regression of established ES cell lines to a
more trophoblast like state and that an increase in expres-
sion of less than two-fold led to differentiation towards the
mesodermal and endodermal states [54]. SOX2 has been
shown to directly interact with OCT3/4, forming a syner-
gistic regulatory complex regulating many pluripotent stem
cell genes. Following on from this Masui et al. [48] have
proposed that the major essential function of SOX2 is to
stabilize ES pluripotency by maintaining the strict levels of
OCT3/4 that a requisite to this undifferentiated state.
In an attempt to try and provide a more comprehensive
and systematic view of markers present on hESC lines
present in different laboratories around the world, the
International Stem Cell Initiative recently characterized 59
hESC lines from 17 laboratories. One of the major con-
clusions of this study indeed conﬁrmed that the lines were
divergent in character; similar expression patterns of all the
above mentioned markers were found along with several
other unique identiﬁers [35].
Research surrounding the potential of hESCs for
regeneration therapies, although real, has encountered
several major obstacles. One of the major, aside from the
ethical issues, has been the high risk of teratoma formation.
Teratomas are in general benign tumours made up of
mixtures of different cell and tissue types caused by the
presence of contaminating co-transplanted differentiated
cells. This risk was demonstrated to be grounded using
animal studies [55]. Although the answer to this potential
danger appeared to be pre-differentiation of hESC before
injection, following experiments showing the apparent
tumour free application of pre-differentiated hESC in ani-
mal models, this could not exclude a potential risk if used
Fig. 1 Annual publication frequency within the ﬁeld of stem cells and cardiac regeneration
Med Biol Eng Comput (2011) 49:723–732 725
123in the human clinical setting. This fear may recently have
been justiﬁed with the ﬁrst description of a patient treated
with multiple injection rounds of foetal neural stem cells
for a neurodegenerative disorder developed a multifocal
brain tumour [3].
3 Bone marrow mononuclear cells (BMCs)
Although the potential for replacement therapy has received
much of its acclaim in ﬁeld of the embryonic stem cell,
perhaps more due to the open ethical discussions sur-
rounding such research, initial studies that recognized the
potential of stem cells were focused on haematopoietic and
bone marrow derived cells [61]. The relative success and
apparent safety of bone marrow replacement therapy, per-
haps then contributed to the rapid cardiac clinical setting of
this cell source. To this day, BMC has been the most fre-
quently tapped source of cells used in clinical studies and
trials aimed at cardiac repair after myocardial infarction.
Typically, BMCs are isolated by aspiration from the iliac
crest of the patient themselves, reducing the risks of
immunological response in terms of cellular therapy. After
an initial phase of processing, often sedimentation or gra-
dient centrifugation, the BMC cell suspension consists of
progenitors of endothelial origin (*4%), mesenchymal
stem cells (\0.1%) and a very small number of so-called
side population cells including a recently identiﬁed very
small embryonic-like stem cell (VSEL) [70, 84]. The rest of
the cellular material, by far the largest portion, is of non-
progenitor type [22]. The heterogeneity of the cell popula-
tion itself and the techniques used for isolation has made the
characterization and comparison of sub-populations using
cell surface markers difﬁcult. Groups have often selected
their own set of markers to deﬁne their set of enriched BMC
derived cells. The cluster of differentiation (CD) antigens
CD14, CD34, CD45 and CD133 [45, 65] have been used to
identify and enrich hematopoietic progenitor cell popula-
tions (reviewed in [71]). Recently, Riekstina and co-work-
ers examined and determined the presence or absence of a
large range of known stem cell markers in an attempt to
characterize the mesenchymal progenitor populations from
a number of sources including human bone marrow. Like
the hESC, the presence of SSEA-4, Oct3/4 and Nanog could
be detected in bone marrow derived Mesenchymal Stem
Cells (MSCs), though SOX2 appeared to be speciﬁcally
absent. Further, all sources of MSCs tested appeared posi-
tive for the cell surface markers CD73, CD90 and CD105
and lacked expression CD34 [59].
As mentioned earlier, one feature that sets BMC and the
sub-derived cell populations has been their rapid imple-
mentation in patient clinical trials. Since the 12 month and
18 month data from a large number of these trials has been
discussed and (meta-)analyzed elsewhere [1, 36, 44, 47],
we shall only discuss three of the longer-term follow-up
clinical trials, though data from such combined analyzes
would seem to support the notion of modest improvement
in cardiac function after acute myocardial infarction. Most
randomized trials have typically only covered a short-term
follow-up of 4–12 months, making assessment of the true
efﬁcacy and sustained effect of such a therapy difﬁcult.
Further, although apparently safe in the short-term appli-
cation, long-term safety issues have been raised based on
reports of associated risks of arrhythmias and calciﬁcation
[81, 87].
The ASTAMI (Autologous Stem cell Transplantation in
Acute Myocardial Infarction) [46], REPAIR-AMI (Rein-
fusion of Enriched Progenitor Cells and Infarct Remodel-
ling in Acute Myocardial Infarction) [5, 62] and BOOST
(BOne marrOw transfer to enhance ST-elevation infarct
regeneration trials) [63] all made use of a randomized
controlled patient study inwhich patients hadreceived,after
percutaneous coronary intervention with stenting, an intra-
coronary injection of BMCs. All three trials found that the
application of BMCs in the clinical setting is safe. However,
only the REPAIR-AMI (2 years follow-up) [5], but not
ASTAMI (3 year follow-up)[11] and BOOST (5 year fol-
low-up) [49] studies, showed a signiﬁcant positive beneﬁt in
left ventricular ejection fraction. This ﬁnding can also be
concluded from the BOOST 18 monthfollow-upresultsand
most other clinical BMC trials, with patients typically dis-
playing a 2–3% improvement in left ventricular function.
However, after this period, as with the ASTAMI study,
BOOST results suggest that this effect steadily declines to
become non-signiﬁcant when compared to control groups.
One can perhaps then conclude from these studies that in the
long-term there is no observable beneﬁt from the adminis-
tration of BMCs to patients that have suffered an AMI.
However, one should perhaps not be too quick to be dis-
missive of this cell source. Early phase results in general do
see some signiﬁcant positive effects. Therefore, the lack of
information as to why these positive effects disappear dur-
ing a longer-term follow-up, demonstrates that a more basic
approach to understanding the actual mechanisms under-
lying the observed effects is essential for correct interpre-
tation of the end results. Understanding the underlying
mechanism one might be able to focus research and boost
the initial as well as sustain these beneﬁcial effects.
One interesting and plausible explanation for at least
some of the short-term positive effects observed could be
the release of paracrine factors by the injected cell source,
which serve to assist recovery of the damaged tissues [15].
Paracrine factors, such as cytokines and growth factors, are
often released by cells surrounding areas of tissue damage,
functioning as, for instance, circulatory chemoattractants
mediating homing of macrophages and stem cells to the
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zation associated with release of VEGF and IGF, ﬁbrosis
and of particular interest in AMI repair down-regulation
thereof (for example HGF [17]) and even cell survival.
This may also go some way to explaining why multiple cell
sources can have positive effects during the ﬁrst few
months of AMI cellular treatment and recovery. To test this
hypothesis, Ziebert and co-workers made use of an
inducible thymidine kinase suicide system to deplete
transplanted cells in animal models [90]. Induction of this
system at speciﬁc time points after cell transplantation was
observed to reduce the normally observed effects of neo-
vascularization and decrease the level of recovery of left
ventricular function and capillary density. Although the
paracrine effects in human clinical trials cannot easily be
determined, BMC have been shown to release such factors
when transplanted into models of ischemia [39, 74].
4 Adipose tissue-derived stem cells (ASC)
Not only is the isolation of bone marrow a rather painful
procedure, but also the absolute number of stem cells
within the bone marrow is low and their molecular signa-
ture is poorly deﬁned. In this respect, adipose tissue could
be an attractive alternative source, as it is most often
abundantly present in people suffering from cardiac dis-
ease, easy to harvest using liposuction, and relatively rich
in stem cells. Adipose tissue has been shown to have more
than 100-fold higher stem cell density than bone marrow
[28]. Adipose tissue gained an interest as a potential cel-
lular source for cardiac regeneration when in vitro exper-
iments showed that dispersed adipose tissue can be induced
to differentiate into cells of various lineages [91] and even
into cardiomyocytes [56]. These experiments revealed that
*0.05% of the plated cells spontaneously differentiated
into cardiomyocytes within 20 days of culture. Infusion of
non pre-selected or pre-selection of CD44 (hyaluronic acid
receptor), CD105 (endoglin) and CD34-negative adipose-
derived cells in animal models of acute myocardial
infarction, displayed an improved LV-ejection fraction and
wall thickness compared to PBS injected controls [8, 16,
75, 89] In contrast to several studies which apparently
demonstrated a loss of infused cells after injection, recent
studies using bioluminescent imaging of luciferase trans-
fected adipose-derived cells could be identiﬁed in the
recipient heart 4 weeks after administration [8]. Histolog-
ical analysis revealed that the adipose-derived cells had
differentiated into cardiomyocytes, smooth muscle cells
and endothelial cells in the infracted region. Moreover,
these cells were found to secrete growth factors, like VEGF
or IGF-I, possibly contributing to the observed enhanced
cardiac function indirectly [7, 8].
Despite several unresolved issues, two double-blind,
randomized, placebo-controlled phase I trials, APOLLO
and PRECISE, were initiated in 2007; APOLLO, Adi-
POse-derived stem ceLLs in the treatment of patients with
ST-elevation myOcardial Infarction, and PRECISE, a
randomized clinical trial of adiPose-deRived stEm and
regenerative Cells in the treatment of patIents with non
revaScularizable ischEmic myocardium (http://clinical
trials.gov). The results of which are expected to be pre-
sented this year (2011). Nevertheless, at the American
Heart Conference in 2010 the 6 month follow-up of the
ﬁrst 14 patients, of which 10 were treated with adipose-
derived stem cells and 4 with placebo, were presented.
Though the patients treated with adopose-derived stem
cells showed a reduction in infarct size, increased myo-
cardial perfusion and ejection fraction, the results did not
reach signiﬁcance most probably due the small sample
groups [24].
5 Skeletal myoblast: a direct source of muscle?
Perhaps one of the most obvious sources of cells for car-
diac repair are skeletal muscle precursors. These skeletal
myoblasts are progenitor cells of adult myoﬁbers with
several features which make them an attractive alternative
to embryonic and somatic stem cells as replacement cell
source; autologous, easy to culture and high scalability in
vitro, and because they are natural precursors of muscle
cells there is a low risk of tumorigenesis. Typically, these
cells are isolated from the thigh muscle and then expanded
in vitro for 3–4 weeks prior to reinjection into the patient.
Although early trials (for short review see [25]) demon-
strate that transplantation of skeletal myoblasts is feasible
and leads to an improvement in heart function in very
short-term follow-ups, longer term measurable effects in
left ventricular eject fraction were lost. Clinical trials
(MARVEL and SEISMIC), however, are ongoing though
results of these trials are scanty, often being announced at
meetings or via company press releases (see http://www.
bioheartinc.com).
Seemingly a perfect source of new muscle, skeletal
myoblasts possess one natural inherent barrier that seriously
limits their use in directed cardiac cell therapies, namely,
unsuitable electrophyiological coupling. Although skeletal
myoblasts can be grafted into the heart and can even be
sustained for a considerable time, coupling between grafts
and resident cardiomyocytes is poor to non-existent leading
to the real risk of conduction slowing and re-entrant
arrhythmias [31]. One approach to try and overcome this
problem is to prevent Cx43 down-regulation,a key gap
junction in cardiac conductance, during skeletal myoblast
differentiation [20, 58]. Sustained expression of Cx43 in
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coupling in model systems, but may not have solved the
problem of arrhythmogenicity [27, 60].
6 Deriving cardiomyocytes by programming
The discovery that co-culturing hESCs with endodermal
cells led to higher numbers of cardiomyocytes within the
differentiating pluripotent population, proved a key initia-
tive in furthering research on cellular replacement strate-
gies [50] reviewed in [80]. This fact, coupled with the
ﬁnding that transplanted ESCs display an inability to self
differentiate into cardiomyocytes in the natural cardiac
milieu demonstrated a need for a more basic understanding
of signals necessary to induce cardiomyogenesis. The dis-
covery that a combination of at least two TGFb-super-
family members could induce cardiac differentiation in
avians and amphibians [78, 79], prompted Laﬂamme et al.
[42] to explore if the same was possible with cultured
hESCs. hESCs pre-treated with activin A followed by
BMP4 showed yields of [30% beating cardiomyocytes.
Later Yang and co-workers adapted and improved this
protocol by including a later phase of WNT inhibition via
DKK (dikkopf homologue 1) and VEGF (vascular endo-
thelial growth factor) treatment [86]. Similar experiments
have also been attempted with BMCs [21, 43].
The advent of techniques to molecularly characterize
cells provided a list of potential factors that could drive
cardiomyogenesis, but at the same time opened a new door
in terms of cellular programming. The possibility of driving
a differentiated cell back towards a more pre-differential
state began as a list of ESC associated genes up-regulated in
the pluripotent state and lost during/after differentiation.
The systematic transfection of combinations of these factors
ﬁnally gave rise to a seemingly magical cocktail of four
transcription factors: Oct3/4, Sox2, Klf4 and Myc, which
when transfected to adult ﬁbroblasts could derive a stem
cell-like state [67]. This technique which has since been
shown to induce pluripotent stem cells (iPS) from many
different types of ﬁbroblast cells, including human ﬁbro-
blasts [68] (technique reviewed in [85]). Although the
ability to derive cardiomyocytes from this potential new cell
source still needs to be fully explored, initial experiments
using animal models appear to demonstrate that human
ﬁbroblast derived iPS cells can potentially restore function
to the damaged myocardium [52].
7 Reprogramming cardiac ﬁbroblasts
Though 90% of the cardiac volume comprises cardiomyo-
cytes,theyonlyconstitute30%ofthecells.Thevastmajority
of the cells in the heart are non-myocytes of which approx-
imately half is cardiac ﬁbroblast [9]. Upon a myocardial
infarction the ventricular wall is rescued from rupture by the
rapid inﬁltration of cardiac ﬁbroblasts, healing the wound
quickly with simple scar tissue. Although in this respect the
cardiac ﬁbroblast is not regenerating the lost myocardium,
but replacing it, the prospect of harnessing this naturally
abundant cell source and altering its function has been a
driving source for recent research into epicardial develop-
ment and function [77, 79]. A challenging though possible
option would be to ﬁrst induce pluripotency [32, 68] and
subsequently differentiate them into cardiomyocytes [69].
Taking ﬁbroblasts as an undifferentiated mesenchymal
precursor cell, one could potentially reprogramme this
abundant cell source into cardiomyocytes directly, circum-
venting the necessity to induce a pluripotent state. Zeisberg
and co-workers demonstrated that this is a realistic possi-
bility, that transduction of the transcription factor MyoD
could induce skeletal muscle differentiation in cardiac
ﬁbroblasts. [26]. Following along these lines, Ieda et al. [34]
identiﬁed key regulators that upon transduction were able to
induce myocardial differentiation of cardiac ﬁbroblasts.
Making use of isolated GFP-negative cardiac cells from
transgenic mice harbouring a GFP driven by alpha-myosin
heavy chain promoter transduction of 14 key developmental
cardiac regulators induced GFP expression. Sequential
removal of single factors revealed that the combination of
the transcription factors GATA4, Mef2c and Tbx5 were
necessary and sufﬁcient to induce this effect. Further anal-
ysis revealed not only the induction of GFP expression, but
also the expression of an array of cardiomyocyte speciﬁc
genes, a genomic methylation status equivalent to cardio-
myocytes and spontaneous contractions. Injection of these
cells into the left ventricular wall of immunosuppressed
mice, revealed GFP-expressing cells at the site of injection.
Nevertheless, the used isolation procedures do not exclude
that cardiac stem cells are co-isolated. To get a handle on
this, the transcription factor cocktail was tested in cKit, Isl1,
or Mesp1 depleted cardiac ﬁbroblasts, and remained func-
tional pointing to a direct reprogramming of cardiac ﬁbro-
blasts rather than inducing cardiac differentiation of
co-isolated stem cells. The next challenge will be to test this
in human cardiac ﬁbroblast and translate it into an approach
that is applicable in vivo in humans.
8 Reﬂection and future perspectives
The clinical application of progenitor cell sources for
cardiac repair rapidly took off with patient trials across
Europe and the United States. The promise of an improved
cardiac function seemed to be a fact and not just ﬁction in
the initial phases of almost all studies. This spurred large
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Although even the more sceptical accepted that initial
results looked promising, the call for a better understanding
of the mechanisms and molecular basis seemed at ﬁrst to
go unheeded as new, better controlled trials, using larger
patient groups, were set-up. Questions as to how the
infused cell source was inducing positive effects went and
remained for a large part, unanswered. Even basic ques-
tions surrounding the actual number and type of cells
surviving in the infarct after their injection caused a great
deal of controversy. As clinical trials progressed and fol-
low-up periods became extended, results began to show a
trend change, tending more towards resembling the placebo
controls with many of the initial positive beneﬁts of cell
therapy being lost over time.
Here, we have tried to present and discuss some of the
basic molecular knowledge and clinical trails which
attempted to apply the various cell sources in compromised
hearts. Although much has been learnt over the past
10 years, many basic scientiﬁc questions remain. Many of
these questions could be answered by studying nature
herself. Understanding how cells develop and differentiate
during normal embryogenesis can provide us with many
answers to the fundamental questions surrounding this
promising area of translational research. One can only hope
that the hype within the scientiﬁc and medical community,
surrounding the ﬁrst clinical trials and the perspectives of
this wonder cure for a growing problem in an aging society,
has not destroyed public conﬁdence in this novel area of
research. Taken at face value, it would now be easy to
dismiss this prospective therapy, just as we are beginning
to understand how it could be converted from hope into
fact by implementing the mechanistic knowledge that has
and is being gained.
A fundamental question that could be posed is why the
regenerative capacity of the human heart to repair itself up
on damage is virtually non-existing and even insufﬁcient to
maintain the number of cardiomyocytes during aging,
while lower vertebrates possess the capacity of heart
regeneration? Inﬁltration of ﬁbroblasts into an ischemic
area, giving rise to scar tissue, could be considered a kind
of ‘quick and dirty’ repair mechanism to prevent heart’s of
animals with a high pressure circulatory blood system,
(simply) from rupturing after the infarct. If, then, it were
possible to assist the damaged heart not only by providing
it with a suitable cell source for repair, but also provide a
better environment for repair by, for instance, reducing
critical hemodynamics and pressures during convales-
cence, nature may be encouraged to take a more favourable
direction in terms of cardiac muscle regeneration.
If it would prove possible to regenerate muscle mass
sufﬁciently, than we should also take into account that
heart failure is not simply due to muscle loss. It should be
kept in mind that about half of the patients suffering heart
failure do no die due of hemodynamic dysfunction, but
rather due to electrical failure and re-infarction. It would,
therefore, be prudent to not only focus on the basic
mechanisms underlying heart muscle cell regeneration but
also to stimulate research into other aspects of heart dis-
ease/failure.
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